Objective-Vascular smooth muscle cells (VSMCs) modulate their phenotype between synthetic and contractile states in response to environmental changes; this modulation plays a crucial role in the pathogenesis of restenosis and atherosclerosis. Here, we identified fibroblast growth factor 12 (FGF12) as a novel key regulator of the VSMC phenotype switch. Approach and Results-Using murine models and human specimens, we found that FGF12 was highly expressed in contractile VSMCs of normal vessel walls but was downregulated in synthetic VSMCs from injured and atherosclerotic vessels. In human VSMCs, FGF12 expression was inhibited at the transcriptional level by platelet-derived growth factor-BB. Gain-and loss-of-function experiments showed that FGF12 was both necessary and sufficient for inducing and maintaining the quiescent and contractile phenotypes of VSMCs. FGF12 inhibited cell proliferation through the p53 pathway and upregulated the key factors involved in VSMC lineage differentiation, such as myocardin and serum response factor. Such FGF12-induced phenotypic change was mediated by the p38 MAPK (mitogen-activated protein kinase) pathway. Moreover, FGF12 promoted the differentiation of mouse embryonic stem cells and the transdifferentiation of human dermal fibroblasts into SMC-like cells. Furthermore, adenoviral infection of FGF12 substantially decreased neointima hyperplasia in a rat carotid artery injury model. Conclusions-In general, FGF family members induce a synthetic VSMC phenotype. Interestingly, the present study showed the unanticipated finding that FGF12 belonging to FGF family, strongly induced the quiescent and contractile VSMC phenotypes and directly promoted VSMC lineage differentiation. These novel findings suggested that FGF12 could be a new therapeutic target for treating restenosis and atherosclerosis.
V ascular smooth muscle cells (VSMCs) are not terminally differentiated cells and can switch between contractile and synthetic phenotypes in response to physiological and pathological stimuli. In normal adult vessels, VSMCs express high levels of SMC-specific contractile proteins such as α-smooth muscle actin (α-SMA), SM22α, and smooth muscle-myosin heavy chain and exhibit a low proliferation rate. In response to vascular injury, VSMCs undergo a phenotypic switch that is characterized by increased cell proliferation and reduced expression of SMCs-specific contractile proteins, which contributes to the pathogenesis of atherosclerosis and restenosis after angioplasty. 1 Therefore, it is imperative to elucidate the regulatory mechanisms underlying this VSMC phenotypic switch.
Fibroblast growth factor 12 (FGF12), which belongs to the FGF family, was initially discovered by searching cDNA databases for sequences homologous to FGFs. 2 Although the sequence and structure of FGF12 are similar to those of other FGF family members, FGF12 may have different biochemical and functional properties. FGF12 does not activate any of the 7 principal FGF receptors on the cell surface. 3 In general, FGF family genes that induce signals through FGF receptors play important roles in angiogenesis, wound healing, and metabolism. Particularly, FGF1 and FGF2 are potent mitogens of VSMCs. 4, 5 These FGFs, which are released from the injured vasculature, stimulate VSMC proliferation and contribute to intimal hyperplasia formation after an injury. However, the biological functions of FGF12 have been only partially studied in neurons, and the role of FGF12 in the vasculature remains unknown. 6, 7 In the present study, we characterized a novel function of FGF12 in vascular biology and found that it was a crucial regulator that governs VSMC phenotypic modulation and differentiation into SMC-like cells. FGF12 strongly induced the quiescent and contractile phenotypes of VSMCs and inhibited neointima formation in injured vessels, unlike other FGF family members such as FGF1 and FGF2.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

FGF12 Is Downregulated in SMCs of Injured and Atherosclerotic Vessels
We first examined the expression pattern of FGF12 in SMCs of injured arteries and atherosclerotic lesions ( Figure 1A ; Figure I in the online-only Data Supplement). FGF12 was highly expressed in α-SMA + SMCs in the medial layers of the normal rat aorta (day 0). However, FGF12 expression was substantially reduced in the neointimal layers of proliferating (Ki67 + ) and noncontractile (α-SMA − ) SMCs on day 7 after balloon injury. On day 15 (when partial recovery was observed), FGF12 expression was upregulated in α-SMA + SMCs in the neointimal layers. Reverse transcriptionpolymerase chain reaction confirmed that injury-induced changes in FGF12 expression were temporally in parallel with the expression pattern of genes encoding SMC contractile markers SM-myosin heavy chain (MYH11), SM22α (TAGLN), and serum response factor (SRF) ( Figure 1B) . In high-fat diet-fed ApoE −/− mice, FGF12 expression almost coincided with α-SMA expression in the aortic plaques ( Figure 1C) . Consistently, immunohistochemical analysis of human carotid atherosclerotic and normal specimens showed selective FGF12 expression in α-SMA + medial SMCs ( Figure 1D ; Figure II in the online-only Data Supplement). These data indicate that FGF12 expression was highly correlated with the contractile phenotype of VSMCs.
FGF12 Induces the Quiescent and Contractile Phenotypes of Human Aortic Vascular SMCs
To investigate whether FGF12 regulated the phenotypic changes in VSMCs, we performed a gain-of-function experiment by transfecting human aortic vascular SMCs (HASMCs) with a vector expressing FGF12 (pFGF12). Comparative analysis of gene expression profiles revealed 362 differentially expressed genes between HASMCs transfected with pFGF12 and 2 control groups (untransfected wild-type HASMCs and HASMCs transfected with an empty vector [pEntry]; Figure 1A ). Gene ontology enrichment analysis of the 362 differentially expressed genes showed that biological processes including the cell cycle were profoundly altered in pFGF12-transfected HASMCs ( Figure IB) . Expression of several genes involved in cell cycle progression was substantially decreased in pFGF12-transfected HASMCs ( Figure 2C ; Figure III in the online-only Data Supplement). Consistently, the proportion of pFGF12-transfected HASMCs in the G1 phase was substantially high compared with control cells ( Figure 2D ). Cell proliferation data also showed that FGF12 overexpression significantly inhibited serum-or platelet-derived growth factor (PDGF)-BB-induced cell proliferation ( Figure 2E-F) . Because growth inhibition of HASMCs is often accompanied with a phenotypic change to the contractile state, we investigated whether FGF12 overexpression inhibited the phenotypic change of HASMCs to the synthetic state by culturing these cells in growth medium containing serum or PDGF-BB. Expression levels of genes encoding SMC contractile markers were low in wild-type or pEntry-transfected HASMCs but were significantly elevated in pFGF12-transfected HASMCs (Figure 2G through 2I; Figure IV in the online-only Data Supplement). These data indicated that FGF12 was sufficient to block HASMCs from undergoing the phenotypic change into the synthetic state on exposure to serum or PDGF-BB.
FGF12 Knockdown Suppresses the Phenotypic Change in HASMCs Into the Quiescent and Contractile States
Next, we investigated whether FGF12 was required to maintain the quiescent and contractile phenotypes of HASMCs. To induce a phenotypic change to the contractile state, HASMCs were cultured in basal medium for 3 days. Cells cultured under these starvation conditions showed an increase in FGF12 expression, concordant with the upregulation of the contractile marker gene MYH11 and downregulation of the cell proliferation marker gene CDK1 ( Figure 3A ; Figure V in the online-only Data Supplement). Next, we knocked down FGF12 expression in starved HASMCs with a small-interfering RNA ( Figure 3B ). FGF12 knockdown substantially blocked the expression of genes encoding SMC contractile markers in starved HASMCs ( Figure 3C and 3D ). In addition, HASMCs transfected with FGF12 small-interfering RNA showed enhanced proliferation, as determined by immunostaining with anti-Ki67 IgG ( Figure 3E and 3F).
PDGF-BB Inhibits FGF12 Transcription by Activating PI3K
Because FGF12 expression was correlated with the contractile phenotype of VSMCs, we hypothesized that FGF12 
FGF12 Inhibits Cell Proliferation Through the p53 Pathway
To understand how FGF12 induces phenotypic change in VSMCs, we examined cDNA microarray data. Several transcriptional targets of p53 were differentially expressed in pFGF12-transfected HASMCs, suggesting that the p53 pathway was activated in these cells. The mRNA levels of genes encoding p53 (TP53) and its direct transcriptional target p21 (CDKN1A) were significantly higher in pFGF12-transfected HASMCs than in control cells ( Figure 5A ). Western blotting also showed that levels of p53 and phosphorylated p53 DEGs were selected using a fold change cut-off of >2.0 and a P <0.05. B, Gene ontology terms of the 362 DEGs were identified using functional annotation clustering from DAVID. P values are plotted using -log2. C, mRNA levels of FGF12 (total and exogenous) and cell cycle-related genes in WT and transfected HASMCs. Reverse transcription-polymerase chain reaction (RT-PCR) analysis was repeated in triplicate and representative gel images are shown. D, FGF12 induces cell cycle arrest in HASMCs. Cell cycle profiles were analyzed by flow cytometry. Representative histograms and cell cycle distributions in WT and transfected HASMCs are shown (triplicate experiments). E and F, FGF12 suppresses serum-and platelet-derived growth factor (PDGF)-BB-induced proliferation of HASMCs, as determined by cell proliferation assay (*P<0.05 vs WT and pEntry, n=5). Cells were cultured in basal medium supplemented with (E) 10% FBS or (F) 50 ng/mL PDGF-BB. G-I, FGF12 suppresses serum-and PDGF-BB-induced decrease in expression of genes encoding SMC contractile markers. HASMCs were cultured in basal medium supplemented with (G) 10% FBS or (H and I) 50 ng/mL PDGF-BB for 3 d. In G and H, the cells were stained with IgGs against α-smooth muscle actin (SMA) and SM-myosin heavy chain. Cells cultured in basal medium were used as starved WT controls; scale bars: 50 μm. In I, the mRNA levels of FGF12, TAGLN, and MYH11 in transfected cells are expressed relative to those in WT cells (set as 1; *P<0.05 vs WT and pEntry, n=4).
FGF12 Directs SMC Differentiation
Because p53-mediated growth arrest is likely to contribute to the maintenance of contractile phenotypes when HASMCs are cultured in growth medium, we investigated whether FGF12 can directly induce the expression of key genes involved in VSMC lineage differentiation. Myocardin and SRF were significantly upregulated in adenovirus FGF12-transfected HASMCs ( Figure 6A ). Given the critical role of myocardin and SRF in VSMC lineage differentiation, we determined whether ectopic expression of FGF12 promoted the differentiation of murine embryonic stem cells to SMCs. After adenovirus-mediated overexpression of FGF12 was confirmed ( Figure 6B ), embryonic bodies (EBs) were cultured in the absence of leukemia inhibitory factor to induce spontaneous differentiation. Immunofluorescence staining and real-time reverse transcription-polymerase chain reaction showed a substantial upregulation of genes encoding SMC markers in adenovirus FGF12-transfected EBs compared with expression in control cells ( Figure 6C and 6D) . We next investigated whether ectopic expression of FGF12 was sufficient for inducing the transdifferentiation of human dermal fibroblasts (HDFs) into SMCs. We observed that FGF12 overexpression strongly enhanced the expression of SMC marker genes in HDFs compared with expression in control cells ( Figure 6E and 6F) . Next, we performed a collagen gel contraction assay to evaluate the contraction ability of adenovirus FGF12-transfected HDFs in response to treatment with a vasoconstrictor, which is one of the requisite characteristics of VSMCs. Carbachol significantly induced the contraction of adenovirus FGF12-transfected HDFs, which was similar to the response observed for HASMCs ( Figure 6G ).
FGF12 Induces the Quiescent and Contractile Phenotypes of HASMCs Through the p38 MAPK Pathway
Previous studies have shown that FGF12 activates p38 MAPK. 8 Because the activation of the p38 MAPK pathway is involved in phenotypic switching and cell cycle arrest of VSMCs, we investigated whether p38 MAPK is required for FGF12-induced phenotypic changes in VSMCs. [9] [10] [11] Western blotting showed that phosphorylation of p38 MAPK was profoundly enhanced in adenovirus FGF12-transfected HASMCs compared with control cells ( Figure 7A) . Inhibition of the p38 MAPK pathway blocked FGF12-induced upregulation of myocardin and SRF , n=5) . B, Western blotting and densitometric quantification of FGF12, p-p53, and p53 in WT and Ad-transfected HASMCs (triplicate experiments). Relative intensities were determined by normalizing to β-actin band intensity (*P<0.05 vs WT and Ad LacZ, n=3). In A and B, WT and transfected HASMCs were cultured in growth medium for 3 d. C, Representative images of FGF12 and p-p53 expression in uninjured (day 0) and injured rat carotid arteries (days 7 and 15 after balloon wire injury). Sections were stained with IgGs against FGF12 and p-p53 (n=3 mice). Nonspecific staining of elastin fibers is observed in NC treated with nonrelevant primary IgGs. D, siRNAmediated knockdown of TP53 expression in HASMCs. Cells were transfected with siRNA (50 nmol/L) against TP53 or with Cont siRNA. At 24 h, mRNA levels were examined by performing real-time RT-PCR. The mRNA levels in siRNA-transfected cells are expressed relative to those in untransfected cells (set as 1; *P<0.05 vs untransfected and Cont siRNA-transfected cells, n=4). E and F, Inhibiting the p53 pathway abolishes the antiproliferation effect of FGF12 on vascular smooth muscle cells. Cell proliferation in growth medium was assessed by Ki67 staining (*P<0.05 vs WT and Ad LacZ, n=5 for E and F, n=4 for G; NS=not significant). In E, WT and adenovirus (Ad)-transfected HASMCs were transfected with TP53 siRNA or Cont siRNA. In F, WT and Ad-transfected HASMCs were incubated with pifithrin (10 μmol/L) or PBS. G and H, Pifithrin attenuates FGF12-induced expression of contractile markers in HASMCs. Ad-transfected HASMCs were cultured in growth medium and treated with pifithrin (10 μmol/L) or PBS. The percentage of SM22α + cells was assessed (*P<0.05, n=4); scale bars, 50 μm.
Overexpression of FGF12 in the Injured Rat Carotid Artery Suppresses Neointima Formation
Finally, we determined whether FGF12 overexpression inhibited the formation of injury-induced neointima. We overexpressed FGF12 in rats subjected to carotid balloon injury by infecting their injured arteries with adenovirus FGF12. Histological analysis on day 14 after the balloon injury showed that adenovirus FGF12 significantly reduced neointima formation by ≈50%, which in turn decreased neointimal area, intima/media ratio, and luminal stenosis compared with those observed in adenovirus LacZ-injected control rats ( Figure 8A and 8B). In the immunofluorescent staining analysis, adenovirus FGF12-treated injured carotid arteries exhibited increased expression of FGF12 and α-SMA, and exhibited a reduced number of Ki67 + cells as compared with adenovirus LacZ controls ( Figure 8C ).
Discussion
In the present study, we identified FGF12 as a novel master regulator of VSMC plasticity and fate. Although FGF12 shares high sequence homology with FGF1 and FGF2, it plays an opposite role for regulating the VSMC phenotypic switch. By performing both in vitro and in vivo experiments, we observed that FGF12 was necessary and sufficient for inducing phenotypic changes in VSMCs to the quiescent and contractile states and that the ectopic expression of FGF12 directly promoted the differentiation of HDFs and murine embryonic stem cells into SMC-like cells.
We found that FGF12 expression was substantially reduced in dedifferentiated SMCs of injured and atherosclerotic vessels in animal and human tissue samples. In HASMCs, FGF12 expression was reduced by stimuli that enhanced VSMC proliferation, including PDGF-BB and serum. Particularly, the potent VSMC mitogen PDGF-BB, which is released in injured vessels, strongly inhibited the transcription of FGF12 by activating PI3K. PI3K is involved in PDGF-BB-induced VSMC phenotypic changes. Several studies have shown that inhibiting PI3K strongly blocks PDGF-BB-induced proliferation and migration of VSMCs, and that PDGF-BBmediated PI3K activation decreases the expression of SMCspecific contractile marker genes. [12] [13] [14] These findings suggest that PI3K-dependent FGF12 downregulation was involved in PDGF-BB-induced VSMC phenotypic changes. Gainand loss-of-function experiments showed that FGF12 was required for inducing and maintaining the quiescent and contractile phenotypes of VSMCs in the presence of PDGF-BB and serum. FGF12 inhibited cell proliferation by activating the p53 pathway, a crucial pathway for regulating VSMC proliferation and neointima formation in injured vessels. 15, 16 In addition, FGF12 strongly enhanced the expression of SRF and its coactivator myocardin, which are key factors involved in VSMC lineage differentiation. FGF12 overexpression was sufficient to trigger the expression of SMC-specific genes in HDFs and murine embryonic stem cells.
FGF12-induced phenotypic changes in VSMCs occurred through the p38 MAPK pathway. Activation of p38 MAPK is required for the expression of genes encoding SMC contractile markers and for inhibiting VSMC cell cycle progression. [9] [10] [11] Recent studies have reported that p38 MAPK is involved in SRF and myocardin expression. During cardiovascular development and VSMC phenotypic modulation, p38 MAPK plays a key role in inducing myocardin expression by activating myocyte enhancer factor 2, an upstream transcription factor of myocardin. 17, 18 In addition, p38 MAPK plays an important role in mediating transforming growth factor β1-induced upregulation of SRF and myocardin in human coronary artery SMCs and fibroblasts. 19, 20 Moreover, p38 MAPK activates the p53 pathway by phosphorylating p53, which in turn promotes the transcription of its downstream targets, including p53 itself through a positive feedback loop. 21, 22 These findings support our result that the p38 MAPK pathway regulates FGF12-induced upregulation of TP53, SRF, and myocardin in HASMCs.
To our knowledge, the present study is the first to address the function of FGF12 in vascular biology. The results of our study indicate that FGF12 is necessary and sufficient for inducing the quiescent and differentiated phenotypes of VSMCs and that it acts as the key regulator of (trans) differentiation into SMC-like cells. Moreover, our results indicate that local delivery of FGF12 into an injured carotid artery prevents the formation of intimal hyperplasia, suggesting that manipulating FGF12 expression can exert therapeutic effects in vascular diseases involving aberrant VSMC phenotypic changes.
